View in EDS HTML Full Text PDF Full Text

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.

Saved in:
Bibliographic Details
Title: ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Authors: Bandi, Dhana Sekhar Reddy1 (AUTHOR), Nagaraju, Ganji Purnachandra1 (AUTHOR), Sarvesh, Sujith1 (AUTHOR), Carstens, Julienne L.1 (AUTHOR), Foote, Jeremy B.2 (AUTHOR), Graff, Emily C.3 (AUTHOR), Fang, Yu-Hua D4 (AUTHOR), Keeton, Adam B.5,6 (AUTHOR), Chen, Xi5,6 (AUTHOR), Valiyaveettil, Jacob5,6 (AUTHOR), Berry, Kristy L.5 (AUTHOR), Bae, Sejong7 (AUTHOR), Akce, Mehmet1 (AUTHOR), Gorman, Greg8 (AUTHOR), Yoon, Karina J.9,10 (AUTHOR), Manne, Upender11 (AUTHOR), Boyd, Michael R.6 (AUTHOR), Buchsbaum, Donald J.12 (AUTHOR), Azmi, Asfar S.13 (AUTHOR), Maxuitenko, Yulia Y.5 (AUTHOR)
Source: Molecular Cancer. 3/13/2025, Vol. 24 Issue 1, p1-17. 17p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14764598
DOI:10.1186/s12943-025-02288-9